Cargando…

Role of gonadotropin-releasing hormone analogues in metastatic male breast cancer: results from a pooled analysis

BACKGROUND: Male breast cancer is a rare malignancy. Despite the lack of prospectively generated data from trials in either the adjuvant or metastatic setting, patients are commonly treated with hormone therapies. Much controversy exists over the use of gonadotropin-releasing hormone analogues in me...

Descripción completa

Detalles Bibliográficos
Autores principales:	Di Lauro, Luigi, Pizzuti, Laura, Barba, Maddalena, Sergi, Domenico, Sperduti, Isabella, Mottolese, Marcella, Amoreo, Carla Azzurra, Belli, Franca, Vici, Patrizia, Speirs, Valerie, Santini, Daniele, De Maria, Ruggero, Maugeri-Saccà, Marcello
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2015
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4440498/ https://www.ncbi.nlm.nih.gov/pubmed/25980944 http://dx.doi.org/10.1186/s13045-015-0147-z

Ejemplares similares

Efficacy of chemotherapy in metastatic male breast cancer patients: a retrospective study
por: Di Lauro, Luigi, et al.
Publicado: (2015)

The Hippo transducers TAZ/YAP and their target CTGF in male breast cancer
por: Benedetto, Anna Di, et al.
Publicado: (2016)

FOLFIRI as a second-line therapy in patients with docetaxel-pretreated gastric cancer: a historical cohort
por: Maugeri-Saccà, Marcello, et al.
Publicado: (2013)

HMG-CoAR expression in male breast cancer: relationship with hormone receptors, Hippo transducers and survival outcomes
por: Di Benedetto, Anna, et al.
Publicado: (2016)

Vitamin D Supplementation and Breast Cancer Prevention: A Systematic Review and Meta-Analysis of Randomized Clinical Trials
por: Sperati, Francesca, et al.
Publicado: (2013)

Analysis of the ATR-Chk1 and ATM-Chk2 pathways in male breast cancer revealed the prognostic significance of ATR expression
por: Di Benedetto, Anna, et al.
Publicado: (2017)

Expression of the Hippo transducer TAZ in association with WNT pathway mutations impacts survival outcomes in advanced gastric cancer patients treated with first-line chemotherapy
por: Melucci, Elisa, et al.
Publicado: (2018)

Outcomes of HER2-positive early breast cancer patients in the pre-trastuzumab and trastuzumab eras: a real-world multicenter observational analysis. The RETROHER study
por: Vici, Patrizia, et al.
Publicado: (2014)

Topographic expression of the Hippo transducers TAZ and YAP in triple-negative breast cancer treated with neoadjuvant chemotherapy
por: Vici, Patrizia, et al.
Publicado: (2016)

The Hippo transducer TAZ as a biomarker of pathological complete response in HER2-positive breast cancer patients treated with trastuzumab-based neoadjuvant therapy
por: Vici, Patrizia, et al.
Publicado: (2014)

Body mass index modifies the relationship between γ-H2AX, a DNA damage biomarker, and pathological complete response in triple-negative breast cancer
por: Barba, Maddalena, et al.
Publicado: (2017)

Anthropometric, clinical and molecular determinants of treatment outcomes in postmenopausal, hormone receptor positive metastatic breast cancer patients treated with fulvestrant: Results from a real word setting
por: Pizzuti, Laura, et al.
Publicado: (2017)

Deep sequencing and pathway-focused analysis revealed multigene oncodriver signatures predicting survival outcomes in advanced colorectal cancer
por: De Nicola, Francesca, et al.
Publicado: (2018)

p53 status as effect modifier of the association between pre-treatment fasting glucose and breast cancer outcomes in non diabetic, HER2 positive patients treated with trastuzumab
por: Vici, Patrizia, et al.
Publicado: (2014)

DNA Damage and Repair Biomarkers in Cervical Cancer Patients Treated with Neoadjuvant Chemotherapy: An Exploratory Analysis
por: Vici, Patrizia, et al.
Publicado: (2016)

Coexisting YAP expression and TP53 missense mutations delineates a molecular scenario unexpectedly associated with better survival outcomes in advanced gastric cancer
por: Pallocca, Matteo, et al.
Publicado: (2018)

Effect of Gender on the Outcome of Patients Receiving Immune Checkpoint Inhibitors for Advanced Cancer: A Systematic Review and Meta-Analysis of Phase III Randomized Clinical Trials
por: Grassadonia, Antonino, et al.
Publicado: (2018)

Predictive significance of DNA damage and repair biomarkers in triple-negative breast cancer patients treated with neoadjuvant chemotherapy: An exploratory analysis
por: Vici, Patrizia, et al.
Publicado: (2015)

Emerging Biological Treatments for Uterine Cervical Carcinoma
por: Vici, Patrizia, et al.
Publicado: (2014)

TRF2 and VEGF-A: an unknown relationship with prognostic impact on survival of colorectal cancer patients
por: Dinami, Roberto, et al.
Publicado: (2020)

Neoadjuvant Sequential Docetaxel Followed by High‐Dose Epirubicin in Combination With Cyclophosphamide Administered Concurrently With Trastuzumab. The DECT Trial
por: Pizzuti, Laura, et al.
Publicado: (2016)

Dual targeting of HER3 and MEK may overcome HER3-dependent drug-resistance of colon cancers
por: Bon, Giulia, et al.
Publicado: (2016)

Gemcitabine-oxaliplatin (GEMOX) as salvage treatment in pretreated epithelial ovarian cancer patients
por: Vici, Patrizia, et al.
Publicado: (2013)

Observational study of coagulation activation in early breast cancer: development of a prognostic model based on data from the real world setting
por: Mandoj, Chiara, et al.
Publicado: (2018)

Multicohort and cross‐platform validation of a prognostic Wnt signature in colorectal cancer
por: Goeman, Frauke, et al.
Publicado: (2020)

“Triple positive” early breast cancer: an observational multicenter retrospective analysis of outcome
por: Vici, Patrizia, et al.
Publicado: (2016)

Fasting glucose and body mass index as predictors of activity in breast cancer patients treated with everolimus-exemestane: The EverExt study
por: Pizzuti, Laura, et al.
Publicado: (2017)

Targeting immune response with therapeutic vaccines in premalignant lesions and cervical cancer: hope or reality from clinical studies
por: Vici, P, et al.
Publicado: (2016)

A Real‐World Multicentre Retrospective Study of Paclitaxel‐Bevacizumab and Maintenance Therapy as First‐Line for HER2‐Negative Metastatic Breast Cancer
por: Gamucci, Teresa, et al.
Publicado: (2016)

Risk of SARS-CoV-2 infection and disease in metastatic triple-negative breast cancer patients treated with immune checkpoint inhibitors
por: Vici, Patrizia, et al.
Publicado: (2020)

SIRT6 interacts with TRF2 and promotes its degradation in response to DNA damage
por: Rizzo, Angela, et al.
Publicado: (2017)

Metabolic Determinants and Anthropometric Indicators Impact Clinical-pathological Features in Epithelial Ovarian Cancer Patients
por: Vici, Patrizia, et al.
Publicado: (2016)

Biomarkers of Response and Resistance to CDK4/6 Inhibitors in Breast Cancer: Hints from Liquid Biopsy and microRNA Exploration
por: Krasniqi, Eriseld, et al.
Publicado: (2022)

Long-Term Safety and Real-World Effectiveness of Trastuzumab in Breast Cancer
por: Mazzotta, Marco, et al.
Publicado: (2019)

Case report: 5-year progression free survival and complete liver response in a patient with metastatic breast cancer treated with everolimus plus exemestane
por: Krasniqi, Eriseld, et al.
Publicado: (2020)

Burnout of health care providers during the COVID-19 pandemic: Focus on Medical Oncologists
por: Vici, Patrizia, et al.
Publicado: (2021)

Non-Pegylated Liposomal Doxorubicin-Cyclophosphamide in Sequential Regimens with Taxanes as Neoadjuvant Chemotherapy in Breast Cancer Patients
por: Vici, Patrizia, et al.
Publicado: (2014)

Prognostic relevance of DNA damage and repair biomarkers in elderly patients with hormone-receptor-positive breast cancer treated with neoadjuvant hormone therapy: evidence from the real-world setting
por: Di Benedetto, Anna, et al.
Publicado: (2019)

DARPP-32 and t-DARPP in the development of resistance to anti-HER2 agents. Pre-clinical evidence from the STEP study
por: Bon, Giulia, et al.
Publicado: (2023)

Observational Multicenter Study on the Prognostic Relevance of Coagulation Activation in Risk Assessment and Stratification in Locally Advanced Breast Cancer. Outline of the ARIAS Trial
por: Pizzuti, Laura, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_jjdvni4fcesj3eqfut2dls1kjh